论文部分内容阅读
目的:探讨沙美特罗氟替卡松治疗哮喘的临床疗效及对肺功能影响。方法:将126例哮喘患者随机分入对照组与观察组,两组患者均接受哮喘常规治疗,给予对照组患者单纯糖皮质激素吸入治疗,观察组患者接受沙美特罗氟替卡松吸入治疗。比较两组治疗有效率及肺功能的改变。结果:观察组与对照组治疗总有效率分别为90.9%和75.0%,差别具有统计学意义(P<0.05);治疗后4周观察组肺功能FVC(%),PEFR和FEV1.0均显著优于对照组(P<0.05)。结论:与单纯吸入糖皮质激素相比,吸入沙美特罗氟替卡松可显著提高哮喘患者临床疗效,改善肺功能。
Objective: To investigate the clinical efficacy of salmeterol fluticasone in the treatment of asthma and its influence on pulmonary function. Methods: One hundred and sixty-six asthmatic patients were randomly divided into control group and observation group. Both groups were given conventional treatment of asthma. Patients in the control group received simple glucocorticoid inhalation. Patients in the observation group received inhaled salmeterol fluticasone. The treatment efficiency and pulmonary function were compared between the two groups. Results: The total effective rates of the observation group and the control group were 90.9% and 75.0%, respectively, with significant difference (P <0.05). The FVC (%), PEFR and FEV1.0 of the observation group were significantly higher than those of the control group Better than the control group (P <0.05). CONCLUSIONS: Salmeterol and fluticasone inhalation, compared with inhaled glucocorticoid alone, significantly improves the clinical efficacy and improves lung function in asthmatic patients.